A Phase 3 clinical trial is underway to assess the combination of SHR-8068, Adebrelimab, and Bevacizumab with TACE in patients with incurable hepatocellular carcinoma.

ClinicalJuly 4, 2026

SHR-8068 Trial in Resectable Hepatocellular Carcinoma Shows Promise

A trial is evaluating SHR-8068 combined with Adebrelimab and Apatinib for resectable hepatocellular carcinoma.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— SHR-8068

July 10, 2026 · N/A

Topline Data

— SHR-8068

July 4, 2026 · N/A

Indications

Hepatocellular Carcinoma →

Therapeutic areas

Hepatocellular Carcinoma →

Oncology →

Oncology · Hepatocellular Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.